235 related articles for article (PubMed ID: 1242153)
1. Abnormal pancreatic glucagon secretion and postprandial hyperglycemia in diabetes mellitus.
Gerich JE; Lorenzi M; Karam JH; Schneider V; Forsham PH
JAMA; 1975 Oct; 234(2):159-5. PubMed ID: 1242153
[TBL] [Abstract][Full Text] [Related]
2. The inhibitory effect of somatostatin on growth hormone, insulin and glucagon secretion in diabetes mellitus.
Ward FR; Leblanc H; Yen SS
J Clin Endocrinol Metab; 1975 Sep; 41(3):527-32. PubMed ID: 1159060
[TBL] [Abstract][Full Text] [Related]
3. Effects of physiologic levels of glucagon and growth hormone on human carbohydrate and lipid metabolism. Studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin.
Gerich JE; Lorenzi M; Bier DM; Tsalikian E; Schneider V; Karam JH; Forsham PH
J Clin Invest; 1976 Apr; 57(4):875-84. PubMed ID: 820717
[TBL] [Abstract][Full Text] [Related]
4. Effects of a long-acting somatostatin analogue on postprandial hyperglycemia in insulin-dependent diabetes mellitus.
Dimitriadis G; Tessari P; Gerich J
Metabolism; 1983 Oct; 32(10):987-92. PubMed ID: 6136893
[TBL] [Abstract][Full Text] [Related]
5. Effect of composition of mixed meals--low- versus high-carbohydrate content--on insulin, glucagon, and somatostatin release in healthy humans and in patients with NIDDM.
Gutniak M; Grill V; Efendić S
Diabetes Care; 1986; 9(3):244-9. PubMed ID: 2873976
[TBL] [Abstract][Full Text] [Related]
6. Influence of somatostatin on carbohydrate disposal and absorption in diabetes mellitus.
Wahren J
Lancet; 1976 Dec; 2(7997):1213-6. PubMed ID: 63040
[TBL] [Abstract][Full Text] [Related]
7. Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus.
Henkel E; Menschikowski M; Koehler C; Leonhardt W; Hanefeld M
Metabolism; 2005 Sep; 54(9):1168-73. PubMed ID: 16125528
[TBL] [Abstract][Full Text] [Related]
8. Effect of intermittent endogenous hyperglucagonemia on glucose homeostasis in normal and diabetic man.
Rizza R; Verdonk C; Miles J; Service FJ; Gerich J
J Clin Invest; 1979 Jun; 63(6):1119-23. PubMed ID: 447838
[TBL] [Abstract][Full Text] [Related]
9. Metabolic effects of somatostatin in maturity-onset diabetes.
Tamborlane WV; Sherwin RS; Hendler R; Felig P
N Engl J Med; 1977 Jul; 297(4):181-3. PubMed ID: 876274
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the suppressive effects of elevated plasma glucose and free fatty acid levels on glucagon secretion in normal and insulin-dependent diabetic subjects. Evidence for selective alpha-cell insensitivity to glucose in diabetes mellitus.
Gerich JE; Langlois M; Noacco C; Lorenzi M; Karam JH; Korsham PH
J Clin Invest; 1976 Aug; 58(2):320-5. PubMed ID: 783198
[TBL] [Abstract][Full Text] [Related]
11. Reduced postprandial hyperglycemia after subcutaneous injection of a somatostatin-analogue (SMS 201-995) in insulin-dependent diabetes mellitus.
Spinas GA; Bock A; Keller U
Diabetes Care; 1985; 8(5):429-35. PubMed ID: 2865093
[TBL] [Abstract][Full Text] [Related]
12. Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM.
Dinneen S; Alzaid A; Turk D; Rizza R
Diabetologia; 1995 Mar; 38(3):337-43. PubMed ID: 7758881
[TBL] [Abstract][Full Text] [Related]
13. The effect of somatostatin on the rise of growth hormone and glucagon secretion induced by arginine and L-dopa in diabetic patients.
Hansen AP; Christensen SE; Lundbaek K
Scand J Clin Lab Invest; 1975 May; 35(3):205-10. PubMed ID: 1153917
[TBL] [Abstract][Full Text] [Related]
14. Postprandial glucose and insulin responses to meals containing different carbohydrates in normal and diabetic subjects.
Bantle JP; Laine DC; Castle GW; Thomas JW; Hoogwerf BJ; Goetz FC
N Engl J Med; 1983 Jul; 309(1):7-12. PubMed ID: 6343873
[TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of somatostatin as a potential ajunct to insulin in the management of diabetes mellitus.
Gerich JE; Schultz TA; Lewis SB; Karam JH
Diabetologia; 1977 Sep; 13(5):537-44. PubMed ID: 908478
[TBL] [Abstract][Full Text] [Related]
16. Postprandial glycaemic effects of a long-acting somatostatin analogue (octreotide) in non-insulin dependent diabetes mellitus.
Williams G; Füessl HS; Burrin JM; Chilvers E; Bloom SR
Horm Metab Res; 1988 Mar; 20(3):168-70. PubMed ID: 2898427
[TBL] [Abstract][Full Text] [Related]
17. Insulin, glucagon, and somatostatin in normal physiology and diabetes mellitus.
Felig P; Wahren J; Sherwin R; Hendler R
Diabetes; 1976 Dec; 25(12):1091-9. PubMed ID: 992227
[TBL] [Abstract][Full Text] [Related]
18. Biphasic effect of somatostatin on oral glucose tolerance in maturity-onset diabetes.
Tamborlane WV; Sherwin RS; Hendler R; Felig P
Metabolism; 1978 Jul; 27(7):849-53. PubMed ID: 661568
[TBL] [Abstract][Full Text] [Related]
19. Studies on the mechanism of epinephrine-induced hyperglycemia in man. Evidence for participation of pancreatic glucagon secretion.
Gerich JE; Lorenzi M; Tsalikian E; Karam JH
Diabetes; 1976 Jan; 25(1):65-71. PubMed ID: 1107095
[TBL] [Abstract][Full Text] [Related]
20. Antidiabetic action of somatostatin after oral glucose loading: due to suppression of glucagon and growth hormone or of intestinal carbohydrate absorption?
Bratusch-Marrain P; Vierhapper H; Grubeck-Loebenstein B; Waldhäusl W; Nowotny P
Horm Metab Res; 1981 Jun; 13(6):305-9. PubMed ID: 6114914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
